Metabolic & Weight
Semaglutide
Semaglutide (GLP-1 receptor agonist)
The most-studied GLP-1 agonist · FDA-approved for type 2 diabetes and obesity
- FDA Status
- FDA-approved · Ozempic (T2D) 2017 · Wegovy (obesity) 2021
- Class
- Modified GLP-1 analog (94% homology) · long-acting
- Sequence
- 31-amino-acid backbone with C18 fatty acid attached at Lys26
- Half-life
- ~165 hours (≈7 days) — once-weekly dosing
Mechanism of action
- GLP-1 receptor agonism → enhanced glucose-dependent insulin release
- Suppresses glucagon secretion from pancreatic α-cells
- Slows gastric emptying → prolonged satiety
- Acts on hypothalamic appetite centers (POMC/CART neurons)
Research areas
- Obesity (Wegovy: ~15% body weight reduction at 2.4 mg)
- Type 2 diabetes (HbA1c reduction ~1.5%)
- Cardiovascular risk reduction (SUSTAIN-6, SELECT trials)
- Investigational: Alzheimer disease, NASH, kidney disease
Evidence and clinical data
The strongest clinical evidence base of any peptide drug. Tens of thousands of patients across SUSTAIN, STEP, SURPASS, SELECT trials. Cardiovascular benefit confirmed in 2024.
Safety profile
Well-characterized safety profile. Common AEs: nausea, vomiting, diarrhea (typically transient). Rare: pancreatitis, gallbladder disease. Black box warning: thyroid C-cell tumors in rodents (relevance to humans uncertain).
Why this peptide is trending in 2026: Cultural moment unprecedented for any peptide. Off-label compounded versions surged in 2023-2024 during shortage of brand product. Now subject of celebrity coverage, GLP-1 supply chain economics, and weight-loss conversation reshape.
Educational use only. PeptideAdvance does not sell Semaglutide, recommend its use, or provide medical advice. The information above is a summary of published research and regulatory status as of April 2026. Some peptides discussed here are not FDA-approved or are restricted under FDA Category 2 — their use outside of authorized clinical research may carry legal and safety implications. Always consult a licensed healthcare professional.